LOGIN  |  REGISTER
Assertio

Waystar to Announce Third Quarter 2024 Financial Results on November 6, 2024

October 14, 2024 | Last Trade: US$27.72 0.30 1.09

LEHI, Utah and LOUISVILLE, Ky., Oct. 14, 2024 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, announced today that it will report financial results for the third quarter ended September 30, 2024, after market close on Wednesday, November 6, 2024. The company will discuss its financial results on a conference call at 4:30 p.m. Eastern Time that same day.

A live audio webcast of the conference call will be available on Waystar's investor relations website at https://investors.waystar.com/news-events/events. The webcast will be archived on the site for those unable to listen in real time.

About Waystar

Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 18 of 22 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 5 billion healthcare payment transactions, including over $1.2 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.

Media Contact
Kristin Lee
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investor Contact
Sandy Draper
This email address is being protected from spambots. You need JavaScript enabled to view it.
502-238-9511

Assertio

Stock Quote

Last Trade: US$27.72
Daily Change: 0.30 1.09
Daily Volume: 599,666
Market Cap: US$4.620B

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB